A new genetic test could help diagnose esophageal cancer up to 8 years before symptoms appear in individuals at a high risk of the disease.
Browsing: Disease Area > Head and neck
Researchers from the University of Southern California Roski Eye Institute (CA, USA) have derived genetic information from retinoblastoma tumors without removing the eye.
Could you give us a brief overview of the SCORES trial? The SCORES trial was a two-part study; the first…
Nivolumab has been given the green light for nivolumab for head and neck cancer via the Cancer Drug Fund.
Lydia Makaroff of the European Cancer Patient Coalition (ECPC, Brussels, Belgium) speaks with Oncology Central about the goals and upcoming projects for the ECPC in 2017.
A recent study has demonstrated that patients with elevated levels of tumor-associated immune cells and CD8 T-cells as well as lower levels of regulatory T-cells exhibit more favorable responses to immunotherapy.
This research article from Biomarkers in Medicine explores the prognostic value of p16INK4A in esophageal squamous cell carcinoma patients.
In this special report from Future Oncology, the interplay between prognostic factors, predictive markers and cancer biology are discussed in relation to chemoprevention strategies for oral cancer.
Data presented at the 2017 European Cancer Congress highlights how twice-daily hypofractionated radiotherapy and chemotherapy in head and neck cancer could reduce recurrence and mortality in head and neck cancer.
A calcium ion channel present in T cells has been identified by researchers as a potential target to reduce growth in head and neck cancer.